Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

S ten Bokkel Huinink, DC de Jong… - European journal of …, 2022 - journals.lww.com
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

S ten Bokkel Huinink, DC de Jong… - European Journal of …, 2022 - journals.lww.com
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

S ten Bokkel Huinink… - European …, 2022 - researchinformation.amsterdamumc …
BACKGROUND: Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of
Crohn's disease. Cessation may be considered in patients with a low risk of relapse. We …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.

S Ten Bokkel Huinink, DC de Jong… - European Journal of …, 2022 - europepmc.org
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

ST Huinink, DC de Jong… - European …, 2022 - scholarlypublications …
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

S ten Bokkel Huinink, DC de Jong… - European journal of …, 2022 - research.rug.nl
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

STB Huinink, DC de Jong, D Nieboer… - European journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

S ten Bokkel Huinink, DC de Jong… - European Journal of …, 2022 - ingentaconnect.com
Background Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's
disease. Cessation may be considered in patients with a low risk of relapse. We aimed to …

[引用][C] Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

SB Huinink, DC Jong, D Nieboer, D Thomassen… - 2022 - repository.ubn.ru.nl
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF
treatment in Crohn's disease Toggle navigation Radboud Repository Toggle navigation View …